APA (7th ed.) Citation

Perez-Garcia, J. M., Gebhart, G., Ruiz Borrego, M., Stradella, A., Bermejo, B., Schmid, P., . . . Llombart-Cussac, A. (2021). Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): A multicentre, randomised, open-label, non-comparative, phase 2 trial. The lancet. Oncology, 22(6), . https://doi.org/10.1016/S1470-2045(21)00122-4

Chicago Style (17th ed.) Citation

Perez-Garcia, Jose Manuel, et al. "Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-adapted Strategy in Patients with HER2-positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-label, Non-comparative, Phase 2 Trial." The Lancet. Oncology 22, no. 6 (2021). https://doi.org/10.1016/S1470-2045(21)00122-4.

MLA (9th ed.) Citation

Perez-Garcia, Jose Manuel, et al. "Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-adapted Strategy in Patients with HER2-positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-label, Non-comparative, Phase 2 Trial." The Lancet. Oncology, vol. 22, no. 6, 2021, https://doi.org/10.1016/S1470-2045(21)00122-4.